Hepion Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis, announced the postponement of its adjourned 2021 Annual Meeting of Stockholders that was to be held on July 23, 2021, at 9:00 a.m. Eastern Time due to a lack of a quorum.
July 23, 2021
· 3 min read
